-
1.发明公开
公开(公告)号：EP3115360A1
公开(公告)日：2017-01-11
申请号：EP15759282.5
申请日：2015-03-04
发明人： ZHANG, Liang , LIU, Chuan , XU, Jinyi , ZHANG, Zhaozhao , CHEN, Zhi , CHAI, Jian , YANG, Zhiqing , LUO, Hairong , ZHANG, Xiangyang
IPC分类号： C07D401/12 , C07C303/44 , C07C309/04 , A61K31/4439 , A61P7/02
CPC分类号： C07D401/12 , C07B2200/13 , C07C303/44 , C07C309/04 , C07D403/12
摘要： The present invention relates to novel crystal forms M and N of dabigatran etexilate mesylate and preparation method and uses thereof, wherein the X-Ray powder diffractogram of the crystal form M has characteristic peaks at the following 2θ diffraction angles: 5.7±0.2°, 6.2±0.2°, 11.2±0.2°, 12.4±0.2°, 18.2±0.2°, 21.4±0.2°, 21.8±0.2° and 23.6±0.2°; and the X-Ray powder diffractogram of the crystal form N has characteristic peaks at the following 2θ diffraction angles: 6.0±0.2°, 11.8±0.2°, 18.2±0.2°, 21.6±0.2°, 24.4±0.2°, 27.7±0.2° and 29.7±0.2°. The crystal forms of the present invention have excellent properties in the aspects of leaching time, biological release, chemical stability and processing adaptability.
摘要翻译： 本发明涉及甲磺酸达比加群酯的新型结晶形式M和N及其制备方法和用途，其中晶型M的X射线粉末衍射图在以下2θ衍射角为5.7±0.2°处具有特征峰， 6.2±0.2°，11.2±0.2°，12.4±0.2°，18.2±0.2°，21.4±0.2°，21.8±0.2°和23.6±0.2°; 晶体形式N的X射线粉末衍射图在以下2θ衍射角处具有特征峰：6.0±0.2°，11.8±0.2°，18.2±0.2°，21.6±0.2°，24.4±0.2°，27.7± 0.2°和29.7±0.2°。 本发明的结晶形式在浸出时间，生物释放，化学稳定性和加工适应性方面具有优异的性能。
-
公开(公告)号：EP3366676A1
公开(公告)日：2018-08-29
申请号：EP15906444.3
申请日：2015-10-20
发明人： XU, Jinyi , ZHANG, Liang , ZHANG, Xiangyang , WANG, Xinzeng , CHAI, Jian , LUO, Hongying , YANG, Zhiqing
IPC分类号： C07D215/227
CPC分类号： C07D215/227 , A61P31/06 , B01D9/0063
摘要： Provided are crystal forms I, II, and III of bedaquiline fumarate, and preparation methods thereof. The crystal forms have high purity, excellent physicochemical properties, and good stability. The preparation methods can effectively improve the quality of products, and are applicable to preparation and mass production of medicines.
-
3.发明公开
公开(公告)号：EP3978493A1
公开(公告)日：2022-04-06
申请号：EP20812533.6
申请日：2020-05-21
发明人： ZHENG, Jianfeng , ZHANG, Liang , ZHAO, Min , SHI, Zhenjuan , LI, Xufei , YANG, Zhiqing
IPC分类号： C07D471/04 , A61P35/00 , A61K31/437
摘要： Crystal forms A, B, C, D, E, F, G and H of a compound represented by formula I and a preparation method therefor, as well as medical uses for the various crystal forms and advantages thereof in various aspects.
-
4.发明公开
公开(公告)号：EP3342778A1
公开(公告)日：2018-07-04
申请号：EP16840785.6
申请日：2016-08-26
发明人： YANG, Zhiqing , ZHANG, Liang , ZHANG, Xiangyang , SHI, Zhenjuan , SU, Di , LUO, Hairong , LUO, Hongying , FU, Dejin
CPC分类号： C07H19/20 , C07B2200/13 , C07H1/06 , C07H19/16
摘要： Provided are a new crystal form of fludarabine phosphate, a preparation method therefor, a pharmaceutical composition containing same, and an application thereof in preparing medicine. Crystal forms I and II of the fludarabine phosphate have excellent properties in terms of solubleness, dissolution rate, chemical stability, and processing adaptability.
-
公开(公告)号：EP3241837A1
公开(公告)日：2017-11-08
申请号：EP15874972.1
申请日：2015-11-11
发明人： GUO, Yanghui , ZHAO, Shiguo , ZHANG, Yue , ZHANG, Liang , YANG, Zhiqing , CHAI, Jian
IPC分类号： C07H19/10 , C07H1/06 , A61K31/7072 , A61P31/14
摘要： The present invention relates to a method for preparing Sofosbuvir crystal form-6. The method is simple in operation, stable in process condition, good in reproducibility, high in yield rate and high in purity, viscous gel-type products are not formed during the process, the problem of blocking of a discharge port is solved, and the method is suitable for mass industrial production and has high economic value.
摘要翻译： Sofosbuvir晶形-6的制备方法技术领域本发明涉及Sofosbuvir晶形-6的制备方法。 该方法操作简单，工艺条件稳定，重复性好，收率高，纯度高，在工艺过程中不形成粘性凝胶型产品，解决了出料口堵塞问题， 方法适用于大量工业生产，具有较高的经济价值。
-
-
-
-
搜索结果
5 条记录 (耗时 0.01 秒)
